MedDataX Logo

A Study That Will Compare the Effect of Two Drugs on Participants With Low Bone Mass and a Recent Hip Fracture

NCT ID: NCT00887354

Last Updated: 2019-09-25

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

224 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-04-30

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will evaluate whether teriparatide is superior to the active comparator in the change from baseline of lumbar spine BMD (bone mineral density) in men and postmenopausal women with low bone mass and a recent pertrochanteric hip fracture.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Comparison of the Effects of 2 Drugs on Lumbar Spine Volumetric BMD in Men With Glucocorticoid-Induced Osteoporosis

NCT00503399

Osteoporosis
COMPLETED PHASE3

Effect of Teriparatide Compared to Risedronate on Back Pain in Women With a Spine Fracture Caused by Osteoporosis

NCT00343252

Osteoporosis, Postmenopausal Back Pain Spinal Fracture
COMPLETED PHASE3

VERtebral Fracture Treatment Comparisons in Osteoporotic Women

NCT01709110

Postmenopausal Osteoporosis
COMPLETED PHASE4

Effects of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis

NCT00670501

Osteoporosis, Postmenopausal
COMPLETED PHASE3

Effect of Teriparatide on Hip Fracture Healing

NCT01473589

Femur Neck Fracture
COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The study has 3 periods: a screening phase, a double-blind, double-dummy treatment phase from the time of randomization to the 26 weeks visit, and an open-label treatment phase of approximately 12 month duration, where participants will continue treatment with the same study drug that they were randomized to.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoporosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Teriparatide

20 micrograms (mcg) a day by subcutaneous injection throughout study.

Placebo oral tablets once a week, to match the active comparator weekly dose, during the double-blind, double-dummy phase only.

Group Type EXPERIMENTAL

Teriparatide

Intervention Type DRUG

Administered subcutaneously

Placebo

Intervention Type DRUG

Weekly: Administered orally

Daily: Administered subcutaneously

Calcium

Intervention Type DIETARY_SUPPLEMENT

Approximately 500 to 1000 mg/day administered orally throughout study.

Vitamin D

Intervention Type DIETARY_SUPPLEMENT

Approximately 800 International Units per day (IU/day) administered orally throughout study.

Risedronate

35 milligrams (mg) risedronate sodium orally once weekly throughout study.

Daily placebo injection, to match the daily experimental drug dose, during the double-blind, double-dummy phase only.

Group Type ACTIVE_COMPARATOR

Risedronate

Intervention Type DRUG

Administered orally

Placebo

Intervention Type DRUG

Weekly: Administered orally

Daily: Administered subcutaneously

Calcium

Intervention Type DIETARY_SUPPLEMENT

Approximately 500 to 1000 mg/day administered orally throughout study.

Vitamin D

Intervention Type DIETARY_SUPPLEMENT

Approximately 800 International Units per day (IU/day) administered orally throughout study.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Teriparatide

Administered subcutaneously

Intervention Type DRUG

Risedronate

Administered orally

Intervention Type DRUG

Placebo

Weekly: Administered orally

Daily: Administered subcutaneously

Intervention Type DRUG

Calcium

Approximately 500 to 1000 mg/day administered orally throughout study.

Intervention Type DIETARY_SUPPLEMENT

Vitamin D

Approximately 800 International Units per day (IU/day) administered orally throughout study.

Intervention Type DIETARY_SUPPLEMENT

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Forteo LY333334

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and postmenopausal women aged ≥50 who have sustained a unilateral, fracture of the trochanteric region
* Lumbar spine BMD and/or femoral neck BMD and/or total hip BMD measurement of the contra lateral hip at least 2.0 SDs (standard deviation) below the average bone mass for young women and men

Exclusion Criteria

* Clinically significant abnormal laboratory values
* History of unresolved skeletal diseases that affect bone metabolism
* Polytrauma participants and participants with fractures at more than one site
Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Eli Lilly and Company

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon-Fri 9AM-5PM eastern time (UTC/GMT-5hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Fort Lauderdale, Florida, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

New Port Richey, Florida, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Orlando, Florida, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

New York, New York, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Durham, North Carolina, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Fargo, North Dakota, United States

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Toronto, Ontario, Canada

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Zagreb, , Croatia

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Klatovy, , Czechia

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Prague, , Czechia

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Odense, , Denmark

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Viborg, , Denmark

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Orléans, , France

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Paris, , France

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Saint-Etienne, , France

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Villeurbanne, , France

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Göttingen, , Germany

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Thessaloniki, , Greece

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Milan, , Italy

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Rome, , Italy

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Mexicali, , Mexico

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Monterrey, , Mexico

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Oslo, , Norway

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Barcelona, , Spain

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Girona, , Spain

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Madrid, , Spain

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Marbella, , Spain

Site Status

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.

Seville, , Spain

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Canada Croatia Czechia Denmark France Germany Greece Italy Mexico Norway Spain

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

B3D-EW-GHDK

Identifier Type: OTHER

Identifier Source: secondary_id

12400

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Comparison Medications in the Treatment of Postmenopausal Women With Osteoporosis
NCT00542984 COMPLETED PHASE3
Back Pain in Patients With Severe Osteoporosis
NCT00761332 COMPLETED
Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis
NCT01753856 COMPLETED PHASE4
Teriparatide Use in Hip Replaced Subjects
NCT00191321 COMPLETED PHASE3
Combination Risedronate - Parathyroid Hormone Trial in Male Osteoporosis
NCT01611571 COMPLETED PHASE3
Effects of Teriparatide or Zoledronic Acid Treatment on Bone in Postmenopausal Osteoporotic Women
NCT00927186 COMPLETED PHASE4
Sequential Use of Teriparatide and Raloxifene HCl in the Treatment of Postmenopausal Women With Osteoporosis
NCT00035256 COMPLETED PHASE4
Comparison of Teriparatide With Alendronate for Treating Glucocorticoid-Induced Osteoporosis
NCT00051558 COMPLETED PHASE3
PTH Comparison in Post Menopausal Women
NCT00543218 COMPLETED PHASE3
2-Year Therapy With Teriparatide vs 1-yr Therapy Followed by 1-Year of Raloxifene or Calcium/Vit D in Severe Postmenopausal Osteoporosis
NCT00191425 COMPLETED PHASE4
Early Effects of Parathyroid Hormone (PTH) on the Proximal Femur
NCT01309399 COMPLETED NA
Effects of Teriparatide in Postmenopausal Women With Osteoporosis
NCT00079924 COMPLETED PHASE4
Combined Administration of Teripapartide and Antiresorptive Agents in Postmenopausal Osteoporosis
NCT01535027 COMPLETED PHASE4
Study of Teriparatide in the Treatment of Postmenopausal Women With Osteoporosis
NCT00532207 COMPLETED PHASE3
A Study of the Treatment of Postmenopausal Women With Osteoporosis
NCT00543023 COMPLETED PHASE3
A Study for Teriparatide in Severe Osteoporosis
NCT00696644 COMPLETED
Effect of Teriparatide on Fracture Healing in Patients With Incomplete Atypical Femur Fractures
NCT01896011 COMPLETED PHASE3
A Study Using Imaging Technology to Measure Changes in Bone Structure After Treatment With Teriparatide
NCT00557310 COMPLETED PHASE4
Fracture (FX) Improvement With Teriparatide: FiX-IT Study
NCT01705587 COMPLETED PHASE4
µMRI of Therapeutic Intervention in Postmenopausal Osteoporosis
NCT01153425 COMPLETED PHASE4
Cyclic Versus Daily Teriparatide on Bone Mass
NCT00668941 UNKNOWN PHASE2
Acute Effect of Teriparatide With Bisphosphonate or Denosumab on Bone Resorption
NCT01750086 COMPLETED PHASE4
Study to Evaluate Effect of Intranasal Teriparatide on Bone Mineral Density in Postmenopausal Women With Low BMD
NCT00624481 WITHDRAWN PHASE2
OPTAMISE: Clinical Effectiveness of Teriparatide After Alendronate or Risedronate Therapy in Osteoporotic Postmenopausal Women
NCT00130403 COMPLETED PHASE4
Combined Use of Teriparatide and Raloxifene in Postmenopausal Women With Osteoporosis
NCT00046137 COMPLETED PHASE3